JP2014532411A5 - - Google Patents

Download PDF

Info

Publication number
JP2014532411A5
JP2014532411A5 JP2014539027A JP2014539027A JP2014532411A5 JP 2014532411 A5 JP2014532411 A5 JP 2014532411A5 JP 2014539027 A JP2014539027 A JP 2014539027A JP 2014539027 A JP2014539027 A JP 2014539027A JP 2014532411 A5 JP2014532411 A5 JP 2014532411A5
Authority
JP
Japan
Prior art keywords
human
polypeptide
mhc
chimeric
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014539027A
Other languages
English (en)
Japanese (ja)
Other versions
JP6285361B2 (ja
JP2014532411A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/062029 external-priority patent/WO2013063340A1/en
Publication of JP2014532411A publication Critical patent/JP2014532411A/ja
Publication of JP2014532411A5 publication Critical patent/JP2014532411A5/ja
Application granted granted Critical
Publication of JP6285361B2 publication Critical patent/JP6285361B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014539027A 2011-10-28 2012-10-26 キメラ主要組織適合複合体(mhc)ii分子を発現する遺伝子改変されたマウス Active JP6285361B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161552584P 2011-10-28 2011-10-28
US61/552,584 2011-10-28
PCT/US2012/062029 WO2013063340A1 (en) 2011-10-28 2012-10-26 Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017157497A Division JP6652529B2 (ja) 2011-10-28 2017-08-17 キメラ主要組織適合複合体(mhc)ii分子を発現する遺伝子改変されたマウス

Publications (3)

Publication Number Publication Date
JP2014532411A JP2014532411A (ja) 2014-12-08
JP2014532411A5 true JP2014532411A5 (enExample) 2015-12-17
JP6285361B2 JP6285361B2 (ja) 2018-02-28

Family

ID=47430036

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014539027A Active JP6285361B2 (ja) 2011-10-28 2012-10-26 キメラ主要組織適合複合体(mhc)ii分子を発現する遺伝子改変されたマウス
JP2017157497A Active JP6652529B2 (ja) 2011-10-28 2017-08-17 キメラ主要組織適合複合体(mhc)ii分子を発現する遺伝子改変されたマウス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017157497A Active JP6652529B2 (ja) 2011-10-28 2017-08-17 キメラ主要組織適合複合体(mhc)ii分子を発現する遺伝子改変されたマウス

Country Status (25)

Country Link
US (7) US8847005B2 (enExample)
EP (4) EP4052572B8 (enExample)
JP (2) JP6285361B2 (enExample)
KR (2) KR102113108B1 (enExample)
CN (3) CN108707608A (enExample)
AU (4) AU2012327205B2 (enExample)
BR (1) BR112014009941B1 (enExample)
CA (1) CA2852962C (enExample)
CY (3) CY1119283T1 (enExample)
DK (3) DK3272214T3 (enExample)
ES (4) ES2640241T3 (enExample)
HR (3) HRP20220616T1 (enExample)
HU (2) HUE034374T2 (enExample)
IL (3) IL231895B (enExample)
IN (1) IN2014CN03892A (enExample)
LT (3) LT3590332T (enExample)
MX (2) MX379060B (enExample)
PL (3) PL3272214T3 (enExample)
PT (3) PT2770822T (enExample)
RS (3) RS63220B1 (enExample)
RU (1) RU2660564C2 (enExample)
SG (3) SG10201909638UA (enExample)
SI (3) SI3590332T1 (enExample)
SM (3) SMT201700437T1 (enExample)
WO (1) WO2013063340A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008054865A2 (en) 2006-04-26 2008-05-08 L-3 Communications Security And Detection Systems, Inc. Multi-source surveillance systems
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
RS63220B1 (sr) 2011-10-28 2022-06-30 Regeneron Pharma Genetski modifikovani miševi sa ekspresijom himernih molekula klase ii glavnog kompleksa histokompatibilnosti (mhc)
SI2818478T1 (sl) 2011-10-28 2017-07-31 Regeneron Pharmaceuticals, Inc. Humanizirani il-6 in receptor il-6
US9848587B2 (en) 2013-02-20 2017-12-26 Regeneron Pharmaceuticals, Inc. Humanized T cell co-receptor mice
SI2958937T1 (sl) 2013-02-22 2018-12-31 Regeneron Pharmaceuticals, Inc. Miš, ki izraža humanizirani poglavitni histokompatibilnostni kompleks
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
AU2014249148B2 (en) 2013-03-11 2020-04-02 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
HRP20231121T1 (hr) 2013-09-23 2023-12-22 Regeneron Pharmaceuticals, Inc. Životinje koje nisu ljudi, koje imaju gen za humanizirani protein koji regulira signale
JP6492095B2 (ja) * 2013-10-15 2019-03-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. ヒト化il−15動物
MY183188A (en) 2013-11-19 2021-02-18 Regeneron Pharma Non-human animals having a humanized b-cell activating factor gene
RS60398B1 (sr) 2014-04-08 2020-07-31 Regeneron Pharma Ne-humane životinje sa humanizovanim fc-gama receptorima
NO2785538T3 (enExample) 2014-05-07 2018-08-04
WO2015196051A1 (en) * 2014-06-19 2015-12-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized programmed cell death 1 gene
US20160081314A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric Antigen Receptors
BR112017010793A2 (pt) 2014-11-24 2017-12-26 Regeneron Pharma animal não humano geneticamente modificado, camundongo, métodos para produzir um animal não humano geneticamente modificado e de triagem de candidatos a fármaco direcionados a um antígeno de interesse, e, modelo de camundongo.
BR112017010490A2 (pt) 2014-12-05 2018-04-03 Regeneron Pharma roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano.
ES2841353T3 (es) 2014-12-09 2021-07-08 Regeneron Pharma Animales no humanos que tienen un gen del grupo de diferenciación 274 humanizado
MX2017012829A (es) 2015-04-06 2018-02-23 Regeneron Pharma Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos.
CN108366548B (zh) 2015-11-20 2021-10-08 瑞泽恩制药公司 具有人源化淋巴细胞活化基因3的非人动物
WO2017136712A1 (en) * 2016-02-04 2017-08-10 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered angptl8 gene
CN109068621B (zh) 2016-02-29 2021-07-20 再生元制药公司 具有人源化的tmprss基因的啮齿类动物
CN109640644B (zh) 2016-06-03 2021-10-26 瑞泽恩制药公司 表达外源末端脱氧核苷酸转移酶的非人动物
JP7361031B2 (ja) 2017-11-30 2023-10-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化trkb遺伝子座を含む非ヒト動物
EP4534560A3 (en) 2018-03-24 2025-06-11 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
IL277355B2 (en) 2018-03-26 2025-01-01 Regeneron Pharma Humanized rodents for testing therapeutic agents
CA3098040A1 (en) 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Non-human animal models of ditra disease and uses thereof
KR20220084296A (ko) * 2019-10-22 2022-06-21 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 형질전환 돼지, 이의 제조 방법 및 용도, 그리고 인간 면역계 마우스를 제조하는 방법
WO2021113297A1 (en) 2019-12-02 2021-06-10 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
CN116981357A (zh) 2021-03-31 2023-10-31 瑞泽恩制药公司 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
US20230417899A1 (en) * 2022-06-27 2023-12-28 Oshkosh Corporation Position tracking for a lift device
CA3265746A1 (en) 2022-09-22 2024-03-28 Regeneron Pharmaceuticals, Inc. GENETICALLY MODIFIED MICE EXPRESSING COMPONENTS OF A HUMAN CELLULAR IMMUNE SYSTEM
EP4654982A1 (en) 2023-01-27 2025-12-03 Regeneron Pharmaceuticals, Inc. Modified rhabdovirus glycoproteins and uses thereof
KR20260074976A (ko) 2023-09-19 2026-05-27 리제너론 파마슈티칼스 인코포레이티드 바이러스 펩티드 및 이의 용도
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof
CN122438694A (zh) 2023-12-19 2026-07-21 瑞泽恩制药公司 Foxp3肽及其用途
WO2025178991A1 (en) 2024-02-21 2025-08-28 Regeneron Pharmaceuticals, Inc. Splicing factor gene mutation-associated neoantigenic peptides and uses thereof
WO2025212991A1 (en) 2024-04-05 2025-10-09 Regeneron Pharmaceuticals, Inc. Rodent models of disease
WO2026006734A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Off-target peptide-mhc complex conformation modeling systems and methods for antigen-recognition molecule development
WO2026006724A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Prame off-target peptides and uses thereof
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69034263D1 (de) 1989-07-25 2009-04-02 Cell Genesys Inc Homologe Rekombination für universelle Donorzellen und chimerische Säugetierzellen
US5574205A (en) 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9100481D0 (en) 1991-01-10 1991-02-20 Inst Nat Sante Rech Med Genetically engineered mice
WO1993005817A1 (en) 1991-09-19 1993-04-01 President And Fellows Of Harvard College Transgenic mhc class i and class ii antigen-deficient mammals
EP0663952A4 (en) 1992-09-11 1997-06-11 Univ California TRANSGENIC ANIMALS HAVING TARGET LYMPHOCYTA TRANSDUCTION GENES.
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
GB9315303D0 (en) 1993-07-23 1993-09-08 Zeneca Ltd Polypeptide
US5965787A (en) 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
US6002066A (en) 1996-01-16 1999-12-14 Ortho Pharmaceutical Corp. H2-M modified transgenic mice
EP0910409A4 (en) 1996-03-05 2003-03-19 Scripps Research Inst RECOMBINANT GENE CONSTRUCTS ENCODING T-CELL RECEPTORS SPECIFIC TO HUMAN-RESTRICTED TUMORANTANTIGENS
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
AU741130B2 (en) 1997-09-16 2001-11-22 Oregon Health Sciences University Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
US6372955B1 (en) 1998-02-17 2002-04-16 Ortho Mcneil Pharmaceutical, Inc. Methods for Producing B cells and antibodies from H2-O modified transgenic mice
CA2325721A1 (en) * 1998-03-30 1999-10-07 Research Development Foundation Corticotropin releasing factor receptor 1-deficient mice
WO2001027291A1 (en) 1999-10-12 2001-04-19 Institut Pasteur Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice
US7067308B1 (en) * 2000-03-28 2006-06-27 Bioagri Corporation Vector for genetically modifying non-human animals
WO2002000933A2 (en) 2000-06-23 2002-01-03 Interleukin Genetics, Inc. Screening assays for identifying modulators of the inflammatory or immune responses
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JPWO2002047474A1 (ja) 2000-12-13 2004-04-15 住友製薬株式会社 Hla−a24発現トランスジェニック動物及びその利用
DK1409646T3 (da) 2000-12-19 2012-08-06 Altor Bioscience Corp Transgene dyr omfattende et humaniseret immunsystem
FR2827302B1 (fr) 2001-07-13 2003-10-10 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
US20040072262A1 (en) 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
US7663017B2 (en) * 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
DE10347710B4 (de) * 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US7745690B2 (en) 2004-03-09 2010-06-29 Nagoya Industrial Science Research Institute Transgenic nonhuman mammal representing the pathologic conditions of human rheumatoid arthritis
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
EP1878798A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies
HU0700534D0 (en) * 2006-11-24 2007-10-29 Mezoegazdasagi Biotechnologiai Transgenic animal with enhanced immune response and method for the preparation thereof
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
EP2262898B1 (en) 2008-03-07 2018-01-24 Regeneron Pharmaceuticals, Inc. Es cell-derived mice from diploid host embryo injection
US20090328240A1 (en) 2008-06-24 2009-12-31 Sing George L Genetically modified mice as predictors of immune response
DK3241435T3 (da) 2009-07-08 2021-08-23 Kymab Ltd Dyremodeller og terapeutiske molekyler
CN101695587B (zh) * 2009-10-21 2012-08-29 上海中山医疗科技发展公司 一种基因修饰及调控的内皮祖细胞捕获支架的制备方法
EP2593551B1 (en) 2010-07-15 2016-09-14 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
WO2012039779A1 (en) 2010-09-24 2012-03-29 The United States Of America As Represented By The Secretary Of The Navy Humanized transgenic mouse model
RS63220B1 (sr) 2011-10-28 2022-06-30 Regeneron Pharma Genetski modifikovani miševi sa ekspresijom himernih molekula klase ii glavnog kompleksa histokompatibilnosti (mhc)
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
US9848587B2 (en) 2013-02-20 2017-12-26 Regeneron Pharmaceuticals, Inc. Humanized T cell co-receptor mice
SI2958937T1 (sl) 2013-02-22 2018-12-31 Regeneron Pharmaceuticals, Inc. Miš, ki izraža humanizirani poglavitni histokompatibilnostni kompleks
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
AU2014249148B2 (en) 2013-03-11 2020-04-02 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
MX2017012829A (es) 2015-04-06 2018-02-23 Regeneron Pharma Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos.

Similar Documents

Publication Publication Date Title
JP7261772B2 (ja) ヒト化t細胞補助受容体を発現するマウス
JP6866409B2 (ja) 遺伝子改変された主要組織適合複合体マウス
Salomonsen et al. Two CD1 genes map to the chicken MHC, indicating that CD1 genes are ancient and likely to have been present in the primordial MHC
JP6796597B2 (ja) 非ヒト動物におけるヒト化t細胞媒介性免疫応答
CN105164154B (zh) 表达人源化主要组织相容性复合物的小鼠
Newberg et al. Importance of MHC class 1 α2 and α3 domains in the recognition of self and non-self MHC molecules
CN108401986B (zh) 表达嵌合主要组织相容性复合物(mhc)ii类分子的基因修饰小鼠
JP2018513683A5 (enExample)
JP2016506761A5 (enExample)
JP6456350B2 (ja) キメラ主要組織適合複合体(mhc)クラスii分子を発現する遺伝子導入マウス
JP2016510998A5 (enExample)
CN105188358A (zh) 表达嵌合的主要组织相容性复合物(mhc)i类分子的转基因小鼠
de Groot et al. A specialist macaque MHC class I molecule with HLA-B* 27–like peptide-binding characteristics
KR20250077529A (ko) 인간 세포 면역계의 성분을 발현하는, 유전자적으로 변형된 마우스
RU2653433C2 (ru) Генетически модифицированные в отношении главного комплекса гистосовместимости мыши
RU2783984C2 (ru) Генетически модифицированные в отношении главного комплекса гистосовместимости мыши
NZ766708B2 (en) Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules